Ciprandi G, Buscaglia S, Cerqueti M P, Saccà S, Tosca M, Canonica G W
Department of Internal Medicine, University of Genoa, Italy.
J Investig Allergol Clin Immunol. 1992 Sep-Oct;2(5):248-52.
Anti-inflammatory drugs, i.e. glucocorticosteroids and NSAIDs (nonsteroidal anti-inflammatory drugs), are often included in the treatment of allergic conjunctivitis. The present study compares the clinical efficacy and safety of topical hydrocortisone, acetylsalicylic acid (ASA) and piroxicam compared to placebo. The trial, designed as a double-blind, randomized and parallel-group treatment, was carried out in a group of 40 patients suffering from seasonal allergic conjunctivitis due to Parietaria pollen, during the pollen season (June-July, 1990). Patients received hydrocortisone 0.1% solution, ASA 1% solution, piroxicam 0.5% solution or placebo as eye drops, all one drop in each eye q.i.d. for 14 days. The symptoms were evaluated at baseline and at the end of treatment by the clinician and by patients on a diary card. The hydrocortisone group showed a rapid and significant improvement during the first week of treatment, while ASA and piroxicam reduced symptomatology during the second week of treatment; this difference was statistically significant. At the end of the trial, the active drugs were comparable with regard to clinical efficacy. A statistically significant difference was observed between the active drugs and placebo, while no statistically significant difference was observed among the three drugs. No serious side-effects were observed. The results demonstrate the clinical efficacy of anti-inflammatory drugs in the treatment of pollen-induced allergic conjunctivitis; they also suggest the use of NSAIDs in long-term treatment, as their efficacy has been shown to be closely comparable to that of steroids, while avoiding the well-known side-effects of the latter in prolonged treatment.
抗炎药物，即糖皮质激素和非甾体抗炎药（NSAIDs），常用于过敏性结膜炎的治疗。本研究比较了局部应用氢化可的松、乙酰水杨酸（ASA）和吡罗昔康与安慰剂相比的临床疗效和安全性。该试验设计为双盲、随机和平行组治疗，在1990年花粉季节（6月至7月）对一组40例因墙草花粉引起季节性过敏性结膜炎的患者进行。患者接受0.1%氢化可的松溶液、1%ASA溶液、0.5%吡罗昔康溶液或安慰剂作为滴眼液，每只眼每日4次，每次1滴，共14天。临床医生和患者通过日记卡对基线和治疗结束时的症状进行评估。氢化可的松组在治疗的第一周显示出快速且显著的改善，而ASA和吡罗昔康在治疗的第二周减轻了症状；这种差异具有统计学意义。在试验结束时，活性药物在临床疗效方面相当。活性药物与安慰剂之间观察到统计学显著差异，而三种药物之间未观察到统计学显著差异。未观察到严重副作用。结果证明了抗炎药物在治疗花粉诱导的过敏性结膜炎中的临床疗效；它们还表明在长期治疗中可使用NSAIDs，因为已证明其疗效与类固醇相当，同时避免了后者在长期治疗中众所周知的副作用。
